Skip to main content

and
  1. Article

    Open Access

    Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

    A. S. Kubasch, P. Peterlin, T. Cluzeau, K. S. Götze, K. Sockel, R. Teipel in Leukemia (2023)

  2. No Access

    Chapter

    Effective Algebraic Analysis Approach to Linear Systems over Ore Algebras

    The purpose of this chapter is to present a survey on the effective algebraic analysis approach to linear systems theory with applications to control theory and mathematical physics. In particular, we show how...

    T. Cluzeau, C. Koutschan, A. Quadrat in Algebraic and Symbolic Computation Methods… (2020)

  3. No Access

    Article

    Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI

    Graft failure remains a severe complication of hematopoietic stem cell transplantation (HSCT). Several risk factors have already been published. In this study, we re-evaluated them in a large cohort who had th...

    T Cluzeau, J Lambert, N Raus, K Dessaux, L Absi, F Delbos in Bone Marrow Transplantation (2016)

  4. No Access

    Article

    Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

    Although next-generation sequencing has allowed for the detection of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) for the majority of mutations...

    D A Sallman, R Komrokji, C Vaupel, T Cluzeau, S M Geyer, K L McGraw, N H Al Ali in Leukemia (2016)

  5. Article

    Open Access

    Total genomic alteration as measured by SNP-array-based molecular karyoty** is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine

    Metaphase cytogenetics (MC) has a major role in the risk stratification of patients with myelodysplastic syndromes (MDSs) and can affect the choice of therapies. Azacitidine (AZA) has changed the outcome of pa...

    T Cluzeau, C Moreilhon, N Mounier, J-M Karsenti, L Gastaud in Blood Cancer Journal (2013)

  6. No Access

    Chapter and Conference Paper

    Symbolic Techniques for Domain Decomposition Methods

    Some algorithmic aspects of systems of PDEs based simulations can be better clarified by means of symbolic computation techniques. This is very important since numerical simulations heavily rely on solving sys...

    T. Cluzeau, V. Dolean, F. Nataf, A. Quadrat in Domain Decomposition Methods in Science an… (2013)

  7. Article

    The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production

    In pathological conditions, the amount of DJ-1 determines whether a cell can survive or engage a cell death program. This is exemplified in epithelial cancers, in which DJ-1 expression is increased, while auto...

    G Robert, A Puissant, M Dufies, S Marchetti, A Jacquel in Cell Death & Differentiation (2012)

  8. No Access

    Article

    Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

    The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20–30% blasts tr...

    R Itzykson, O Kosmider, T Cluzeau, V Mansat-De Mas, F Dreyfus, O Beyne-Rauzy in Leukemia (2011)

  9. No Access

    Article

    CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia

    M C Guastadisegni, A Lonoce, L Impera, F Di Terlizzi, G Fugazza, S Aliano in Leukemia (2010)

  10. No Access

    Article

    Pneumoblastoma: a rare lung tumour occurring as a long-term complication after allogeneic haematopoietic cell transplantation

    T Cluzeau, A Sirvent, S Lassalle, J Mouroux, N Mounier in Bone Marrow Transplantation (2010)

  11. No Access

    Article

    Que reste-t-il de l’interféron en hématologie ?

    Interferon alpha has been investigated in haematology since the end of the 60’s. It may be prescribed in various indications but the availability of the recently developed targeted therapies makes necessary to...

    T. Cluzeau, N. Mounier in Oncologie (2008)